Ignite Creation Date:
2025-12-24 @ 1:41 PM
Ignite Modification Date:
2026-01-01 @ 1:49 PM
Study NCT ID:
NCT06051695
Status:
RECRUITING
Last Update Posted:
2025-12-12
First Post:
2023-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Sponsor:
A2 Biotherapeutics Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Solid Tumor, Adult | View |
| None | Colorectal Cancer | View |
| None | NSCLC | View |
| None | Non Small Cell Lung Cancer | View |
| None | NSCLC, Recurrent | View |
| None | Non-Small Cell Squamous Lung Cancer | View |
| None | Pancreas Cancer | View |
| None | Pancreatic Neoplasm | View |
| None | Colorectal Adenocarcinoma | View |
| None | CRC | View |
| None | Colon Cancer | View |
| None | Rectal Cancer | View |
| None | Cancer | View |
| None | Ovarian Cancer | View |
| None | Ovarian Neoplasms | View |
| None | Mesothelioma | View |
| None | Mesothelioma, Malignant | View |
| None | Ovary Cancer | View |
| None | Lung Cancer | View |
| None | MESOM | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CAR T Cell | View |
| None | Solid Tumors | View |
| None | Autologous | View |
| None | T Cell | View |
| None | Mesothelin | View |
| None | MSLN | View |
| None | HLA-A2 | View |
| None | Solid Tumors expressing MSLN | View |
| None | Pancreatic | View |
| None | Cell Therapy | View |
| None | Gene Therapy | View |
| None | blocker | View |
| None | Cancer | View |
| None | PANC | View |
| None | CRC | View |
| None | Colorectal Cancer | View |
| None | Lung Cancer | View |
| None | NSCLC | View |
| None | OVCA | View |
| None | MESOM | View |
| None | Ovarian Cancer | View |
| None | Mesothelioma | View |
| None | Logic-gate | View |